PL441111A1 - Sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych do współdostarczania leków przeciwgruźliczych oraz ich zastosowanie - Google Patents

Sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych do współdostarczania leków przeciwgruźliczych oraz ich zastosowanie

Info

Publication number
PL441111A1
PL441111A1 PL441111A PL44111122A PL441111A1 PL 441111 A1 PL441111 A1 PL 441111A1 PL 441111 A PL441111 A PL 441111A PL 44111122 A PL44111122 A PL 44111122A PL 441111 A1 PL441111 A1 PL 441111A1
Authority
PL
Poland
Prior art keywords
application
delivery
obtaining
graft polymers
tuberculosis drugs
Prior art date
Application number
PL441111A
Other languages
English (en)
Other versions
PL246891B1 (pl
Inventor
Dorota Neugebauer
Katarzyna Niesyto
Original Assignee
Politechnika Śląska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Śląska filed Critical Politechnika Śląska
Priority to PL441111A priority Critical patent/PL246891B1/pl
Publication of PL441111A1 publication Critical patent/PL441111A1/pl
Publication of PL246891B1 publication Critical patent/PL246891B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Przedmiotem zgłoszenia jest sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych do współ dostarczania leków przeciwgruźliczych, który polega na tym, że koniugat z fusydanem w ilości od 0,01 g do 1 g rozpuszcza się od 100 do 120-krotnym, korzystnie w 100-krotnym nadmiarze rozpuszczalnika polarnego, korzystnie metanolu, po czym dodaje się ryfampicynę w stosunku wagowym 1:1, następnie wkrapla się wodę, korzystnie dejonizowaną, dwukrotny nadmiar w stosunku do objętości użytego rozpuszczalnika, miesza w czasie 12 - 48 h, korzystnie w czasie 24 h w temperaturze pokojowej, odparowuje rozpuszczalnik i liofilizuje. Przedmiotem zgłoszenia jest również zastosowanie nowych układów otrzymanych sposobem określonym powyżej do terapii skojarzonej, leczenia chorób o podłożu bakteryjnym, wymagających terapii wielolekowej oraz wykorzystanie koniugatów do enkapsulacji rifampicyny w rozpuszczalnikach polarnych.
PL441111A 2022-05-05 2022-05-05 Sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych oraz ich zastosowanie PL246891B1 (pl)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL441111A PL246891B1 (pl) 2022-05-05 2022-05-05 Sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych oraz ich zastosowanie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441111A PL246891B1 (pl) 2022-05-05 2022-05-05 Sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych oraz ich zastosowanie

Publications (2)

Publication Number Publication Date
PL441111A1 true PL441111A1 (pl) 2023-11-06
PL246891B1 PL246891B1 (pl) 2025-03-24

Family

ID=88651418

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441111A PL246891B1 (pl) 2022-05-05 2022-05-05 Sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych oraz ich zastosowanie

Country Status (1)

Country Link
PL (1) PL246891B1 (pl)

Also Published As

Publication number Publication date
PL246891B1 (pl) 2025-03-24

Similar Documents

Publication Publication Date Title
MX2022006033A (es) Lipidos ionizables y composiciones de nanoparticulas de estos.
CY1105652T1 (el) Διασπειρομενη διαμορφωση αντιφλεγμονωδους μεσου
MX2021005808A (es) Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
TR200100411T2 (tr) 2-(Pürin-9-il)-tetrahidrofuran-3,4-diol türevleri.
BR0116690A (pt) Composição cosmética, método para conferir volume e/ou comprimento aos cìlios e composição de máscara
BR0114648A (pt) Composição antiperspirante e/ou desodorante clara
NO20026064D0 (no) Nye forbindelser
JOP20240250A1 (ar) مركبات واستخداماتها
US20190338060A1 (en) Polymer Comprising Certain Level Of Bio-Based Carbon
CY1114260T1 (el) 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγο, μεθοδοι για την παραγωγη αυτου και χρηση αυτου για την αγωγη παθησεων
MX2023014855A (es) Lípidos catiónicos y composiciones de estos.
JP2020513461A (ja) ある特定のレベルのバイオベース炭素を含むポリマー
Modarresi-Alam et al. Dynamic 1H NMR spectroscopic study of the restricted SN rotation in aryl-N-(arylsulfonyl)-N-(triphenylphosphoranylidene) imidocarbamates
DK330783A (da) Fremgangsmaade til fremstilling af furanonderivater
ATE374960T1 (de) Mit säure abbaubare harzzusammensetzungen mit ketenaldehyd-copolymer
CO2023005889A2 (es) Formulación de conjugado anticuerpo-fármaco de ceacam5
PL441111A1 (pl) Sposób otrzymywania układów micelarnych koniugatów jonowych na bazie polimerów szczepionych do współdostarczania leków przeciwgruźliczych oraz ich zastosowanie
ATE417856T1 (de) Motilidverbindungen
BR0312033A (pt) Formulações para depósito de curta duração
CN105061701A (zh) 含有腙键的具有靶向抗肿瘤活性的嵌段共聚物及其制备和作为抗肿瘤药物载体的应用
PL438371A1 (pl) Układ fotoinicjujący polimeryzację rodnikową tworzyw sztucznych i jego zastosowanie
PL446973A1 (pl) Sposób otrzymywania micelarnych koniugatów jonowych na bazie polimerów szczepionych do współdostarczania leków przeciwbakteryjnych oraz ich zastosowanie
PL438370A1 (pl) Układ fotoinicjujący polimeryzację rodnikową akrylanów i jego zastosowanie
ES505329A0 (es) Procedimiento para la preparacion de derivados de imidazol del sistema de 1,4-benzodioxan-2-ilo
PL446972A1 (pl) Sposób otrzymywania micelarnych koniugatów jonowych na bazie polimerów liniowych do współdostarczania leków przeciwgruźliczych oraz ich zastosowanie